Plain-English translation of NCT06147986 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing UMSC01, a type of stem cell derived from umbilical cord tissue, as an additional treatment for people who have recently had a heart attack (within 12 hours of symptoms starting). After you receive standard emergency heart attack care (including a procedure to unblock your artery), you would receive the medication through two infusions: one directly into your heart artery about 4–5 days after the attack, and another through your vein 2 days later. The goal is to see whether this treatment helps your heart muscle heal and function better.
After a heart attack, the heart muscle is damaged and may not pump as well as it should. Standard treatments save lives but don't always fully restore heart function. This trial is exploring whether stem cells—which may reduce inflammation and promote healing—can improve heart recovery when added to standard care.
You likely qualify if…
You likely don't qualify if…
After you are enrolled and stabilized from your recent heart attack, you would return to the hospital on days 4–5 after your heart attack for the first infusion, where the stem cells would be delivered directly into your heart artery during a catheterization procedure. Two days later, you would receive the second infusion through an IV in your arm. You would then be monitored with follow-up visits and heart imaging to see how well your heart recovers over time.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Taiwan